Buglioni S, D'Agnano I, Vasselli S, Perrone Donnorso R, D'Angelo C, Brenna A, Benevolo M, Cosimelli M, Zupi G, Mottolese M
Pathology Department, Regina Elena Cancer Insititute, Via Chianesi 53, 00144 Rome, Italy.
Am J Clin Pathol. 2001 Sep;116(3):360-8. doi: 10.1309/V7UW-UT2E-JVYH-DGWK.
To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and polyclonal antibody CM1, were determined in 94 surgically resected stage II (Dukes B2) colorectal cancers, treated or not with adjuvant 5-fluorouracil-based chemotherapy. Sixty-one (65%) of the tumors were aneuploid, 16 (17%) of which had a multiploid DNA content; 50 (53%) displayed DO7 nuclear p53 accumulation, and 44 (47%) showed cytoplasmic CM1 positivity. In multivariate analysis, only multiploidy and p53 nuclear positivity emerged as independent prognostic indicators of a poorer outcome. Positivity for p53 was associated with shorter survival in 5-fluorouracil-treated and untreated patients. Therefore, in patients with Dukes B2 colorectal cancer, a biologic profile based on the combined evaluation of DNA multiploidy and p53 status can provide valuable prognostic information, identifying patients to be enrolled in alternative, more aggressive therapeutic trials.
为了确定预后风险最高的患者，我们对94例手术切除的II期（Dukes B2）结直肠癌患者进行了DNA含量以及通过单克隆抗体DO7和多克隆抗体CM1评估的p53核内或胞质蓄积情况的检测，这些患者接受或未接受基于5-氟尿嘧啶的辅助化疗。61例（65%）肿瘤为非整倍体，其中16例（17%）具有多倍体DNA含量；50例（53%）显示DO7核内p53蓄积，44例（47%）显示胞质CM1阳性。多因素分析显示，只有多倍体和p53核阳性是预后较差的独立预后指标。p53阳性与5-氟尿嘧啶治疗组和未治疗组患者的生存期缩短相关。因此，对于Dukes B2期结直肠癌患者，基于DNA多倍体和p53状态联合评估的生物学特征可提供有价值的预后信息，从而确定可纳入替代的、更积极治疗试验的患者。
